相关临床试验
642
187 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
40
6.2%
已完成
83
12.9%
Enrolling By Invitation
12
1.9%
尚未招募
135
21.0%
招募中
235
36.6%
暂停
1
0.2%
终止
6
0.9%
Unknown
123
19.2%
撤回
7
1.1%
暂无批准数据
- Juventas Cell Therapy's Inaticabtagene Autoleucel (YORWIDA) received NMPA approval for treating relapsed or refractory Large B-Cell Lymphoma after two or more lines of systemic therapy. - The approval makes Ina-cel the first proprietary CD19 CAR-T product in China with full intellectual property rights to cover both leukemia and lymphoma indications. - The approval was based on positive results from a multi-center Phase II clinical study demonstrating durable remission and long-term survival benefits with excellent safety profile. - Clinical data showed no cases of Grade 3 or higher Cytokine Release Syndrome and only one patient experiencing Grade 3 or higher neurotoxicity syndrome.
- A clinical trial of deep brain stimulation (DBS) targeting the bed nucleus of the stria terminalis and nucleus accumbens achieved a 50% response rate and 35% remission rate in 26 patients with treatment-resistant depression. - Researchers identified that lower theta brain activity in the BNST and stronger BNST-prefrontal cortex coherence before surgery predicted better treatment outcomes at 3, 6, and 12 months. - The study revealed that DBS reduced BNST theta activity in parallel with symptom improvement, opening possibilities for real-time, closed-loop stimulation systems that could adjust treatment based on brain activity patterns. - Neuropsychological assessments showed that patients with stronger negative emotional reactions to unpleasant images were less likely to benefit from DBS treatment.
- Guangdong Zhongsheng Pharmaceutical has completed enrollment and dosing of the first participant in a Phase III clinical trial for Angladivir granules targeting influenza A in children aged 2-11 years. - The granule formulation is designed to facilitate medication use among children and patients with swallowing difficulties, building on positive Phase II results demonstrating efficacy and safety. - Angladivir represents the world's first Class I innovative drug targeting the PB2 subunit of influenza A virus RNA polymerase, with the tablet form already approved for adult treatment in May 2025. - The company is simultaneously advancing multiple Phase III trials including Angladivir tablets for adolescents aged 12-17 and RAY1225 injection for obesity and diabetes treatment.
- The first patient treated with UX-DA001, an iPSC-derived autologous cell therapy for Parkinson's disease, demonstrated a 47.7% improvement in motor function scores during OFF periods at 6-month follow-up. - Daily OFF time was reduced by 3.6 hours while ON time without troublesome dyskinesia increased by 3.3 hours, with no serious adverse events reported. - PET imaging confirmed graft survival and functional integration, showing increased dopamine transporter signals in transplanted brain regions. - UX-DA001 is the world's first autologous cell therapy for Parkinson's disease to receive clinical trial approval in both China and the United States.
- Researchers developed a multivariate prediction model using skeletal muscle radiation attenuation (SMRA), neutrophil-to-lymphocyte ratio (NLR), and weight loss to identify gastric cancer patients who would benefit from chemotherapy plus PD-1 antibody treatment. - The model achieved superior predictive accuracy with an AUC of 0.728 compared to individual parameters, successfully stratifying patients into good responders (67.3% achieving tumor regression) versus poor responders (27.7%) in both training and validation cohorts. - Patients classified as good responders by the prediction model demonstrated significantly better overall survival outcomes, suggesting this accessible clinical tool could optimize immunotherapy selection for gastric cancer patients.
- Two Chinese medical technology companies, NanoVision Technology and Shanghai United Imaging Healthcare, have simultaneously launched clinical trials for breakthrough CT imaging systems at Shanghai hospitals. - NanoVision's phased array CT scanner delivers ultra-high-definition images with 3072x3072 resolution and reduces radiation dose by over 50 percent using a unique photon stream detector technology. - Shanghai United Imaging's photon-counting spectral CT system provides multi-spectral imaging that maps tissue components in exquisite detail while reducing radiation exposure by 60-90 percent. - Both technologies promise to revolutionize early disease detection and precision diagnostics, with applications ranging from pulmonary pathology to cardiac imaging and orthopedic procedures.
- Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion. - A pivotal Phase 3 trial involving 333 patients across 28 Chinese hospitals demonstrated that IV Fluimucil was significantly superior to placebo and non-inferior to ambroxol in reducing sputum viscosity. - The approval follows a robust local clinical development program including Phase 1 and Phase 3 studies that confirmed the drug's safety, tolerability, and efficacy profile. - The launch marks Zambon's expansion in the Chinese market and celebrates the 60th anniversary of the Fluimucil molecule.
- CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment. - HM2002 achieved dual regulatory approval, having previously received IND clearance from China's NMPA in January 2025, making it the only circular RNA therapy approved in both countries. - The drug demonstrated significant cardiac function improvement without drug-related adverse events in its first-in-human trial at Ruijin Hospital. - HM2002 addresses critical unmet medical needs in ischemic heart disease by promoting angiogenesis through controlled VEGF expression in the myocardium.
